- Medexus Pharmaceuticals press release (OTCQX:MEDXF): Q4 Adjusted EBITDA of $4.4 million in fiscal Q4 2024, a decrease of $0.4 million, or 8.8%, compared to $4.8 million in fiscal Q4 2023.
- Adjusted net income of $0.8 million for fiscal Q4, 2024.
- Revenue of $26M (-9.1% Y/Y) misses by $0.68M.
- Available liquidity of $5.3 million (March 31, 2024), consisting of cash and cash equivalents, compared to $13.1 million (March 31, 2023).
- Cash provided by operating activities of $18.7 million for fiscal year 2024.
2024-06-26